August 25, 2021

Early stage biotech companies have traditionally had limited options to get their first asset to market: in most cases, they pursue deals with larger partners, losing control of their intellectual property and limiting their future financial returns, or become a fully integrated company through heavy investment and a great deal of risk. 

This article dissects considerations for how to reduce risk, manage costs and optimize performance while maintaining control of your asset.

Scroll to Page Bottom Form 
Powered by GlobalLink OneLink Software